Drugs / Peptide-tet
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01532960 | Jul 2012 → Sep 2015 | breast cancer | Craig L Slingluff, Jr | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peptide-tet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01532960 ↗ |
| Modality | Peptide | “a helper peptide derived from tetanus toxoid” PMID 29157306 ↗ Nov 2017 |
| Route | Intramuscular | “The vaccine will be administered intramuscular (IM) (1 ml) and intradermally (ID) (1 ml) at vaccination sites in the arm and leg.” NCT01532960 ↗ |
| Route | Other | “The vaccine will be administered intramuscular (IM) (1 ml) and intradermally (ID) (1 ml) at vaccination sites in the arm and leg.” NCT01532960 ↗ |